PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Parea Paro Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known		
INFORMATION DISCLOSURE				Application Number 10/066,057		
				Filing Date	January 31, 2002	
STATEMENT BY APPLICANT (use as many sheets as necessary)			NI	First Named Inventor Michael B. Zemel, et		
			ssary)	Art Unit	1617	
				Examiner Name	Helen Nguyen	
Sheet	1	of	2	Attorney Docket Number	UTR-104D1	

			U.S. PATENT D	OCUMENTS	
Examiner Initials*	Cite No. 1	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
8	U1	US- 3,621,024	11-16-1971	Nieper	Entire document
	U2	US- 5,914,326	06-22-1999	McCarty et al.	Entire document, Example 1
(/	U3	US- 6,136,349	10-24-2000	Karppanen et al.	Entire document
1	U4	US-			405
- 0	U5	US-			HILD.
	U6	US-			1/0/3/ A
	U7	US-			000012 4
	U8	US-			1000
	U9	US-			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. 1	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁴	
0-	F1	BE 723,952	04-16-1969	Nieper	Page 3		
X	F2	WO 98/28989	07-09-1998	Karppanen Pasi Heikki	All	•	
	F3	WO 99/03464	01-28-1999	Raju Ganga; Interhealth Nutraceuticals, Inc.	Claims		
A	F4	WO 99/11254	03-11-1999	Kish Octrooibureau	Pgs. 2-6; claims		
1	F5						
Ü	F6						
	F7.						

Examiner	Date	· ·	/
I	Considered	<i>y</i> ,	103
Signature	Considered		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

2

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

of

Complete if Known				
Application Number	10/066,057			
Filing Date	January 31, 2002			
First Named Inventor	Michael B. Zemel, et al.			
Group Art Unit	1617			
Examiner Name	Helen Nguyen			
Attorney Docket Number	UTR-104D1			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
7	R1	SANWA KAGAKU KENKYUSHO CO, "Stabilised Oligo Peptide Composition for Sleep-Improving Drug Containing Oligo-Peptide and Bovine Bone Powder as Calcium Salt, for Obesity Treatment, etc.," Database WPI, Section Ch, Week 199028, Derwent Publications Ltd., London, GB; Class B04, AN 1990-214417, XP002206900 & JP 02 145525 A, 5 June 1990 - abstract	
	R2	MEIJI SEIKA KAISHA, "Food Compound for Overweight Clients – Obtained by Blending Water Soluble Dietary Fibers and Insoluble Calcium Compound in Acidic Conditions, e.g., Gastric Juice," Database WPI, Section Ch, Week 199211, Derwent Publications Ltd., London, GB; Class D13, AN 1992-083488, XP002206898 & JP 04 023968 A, 28 January 1992 - abstract	
7	R3	MEIJI SEIKA KAISHA, "Diet or Diabetic Food – Contains Water-Soluble Food Fiber, Preferably Arginic Acid (Salt), and Insoluble Calcium Compound," Database WPI, Section Ch, Week 199532, Derwent Publications Ltd., London, GB; Class B04, AN 1995-242723, XP002206899 & JP 07 147935 A, 13 June 1995 - abstract	
V	R4		
	R5		
	R6		
	R7	THE CENTER OF TH	
	R8		
	R9		
	R10	BEST AVAILABLE COPY	
	R11	DEST AVAILABLE 331	
	R12		

	· · · · · · · · · · · · · · · · · · ·		
Examiner		Date	N/AD
Signature		Considered	8/03

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.